We found that the comprehensive WHO-recommended AHD package, including a CD4 count to diagnose AHD, would result in the greatest life expectancy and would be cost-effective (incremental cost-effectiveness ratio US$580 per quality-adjusted life-year) compared with no availability of the AHD package or only some of the components. This evidence concerns the gene CD4 and mitochondrial DNA depletion syndrome 4a.